Remove Bioavailability Remove Clinical Trials Remove Trials
article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. Proceeds from the IPO will propel key initiatives, including the Phase II clinical trial of Jotrol in Parkinson’s disease.

article thumbnail

CellCentric Strengthens Leadership Team

Pharma Mirror

CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications. Both have stellar experience and track records in oncology research and development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Obesity-Focused Metsera Launches IPO Amid Much Anticipation

XTalks

XTALKS WEBINAR: GLP-1 Agonist Development: Endpoint Strategies to Help Differentiate Your Drug Live and On-Demand: Tuesday, February 25, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how innovative digital and imaging endpoints can maximize the value of GLP-1 clinical trials. in its Phase Ib trial.

article thumbnail

Orphagen’s ACC therapy receives FDA rare pediatric disease status

Pharmaceutical Technology

OR-449 is a first-in-class, orally bioavailable, potent and selective small molecule antagonist of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1). We currently plan to file an Investigational New Drug (IND) application with the FDA later this year to support the initiation of a Phase I clinical trial. “We

article thumbnail

BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers

Pharmaceutical Technology

Brukinsa is a small-molecule Bruton’s tyrosine kinase (BTK) inhibitor specially designed for delivering sustained and targeted BTK protein inhibition by optimising bioavailability, half-life, and selectivity. The regulatory approval for the BTK inhibitor to treat CLL was based on Phase III SEQUOIA and ALPINE clinical trials.

Marketing 130
article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

cyclosporine A) is currently at pre-registration stage with the FDA, following results from late-stage clinical trials that demonstrated CyclASol significantly reduced corneal and conjunctival staining, and improved ocular dryness compared with vehicle. Novaliq’s CyclASol (0.1%

article thumbnail

China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL

Pharmaceutical Technology

The small molecule Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity.